An observational study in Bulkamid® for Urinary Incontinence, Urinary Incontinence and Ultrasound, sponsored by Hospices Civils de Lyon. Completed at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Hospices Civils de Lyon · Observational
Bulkamid filler is a gel that we use very regularly to treat female urinary leakage during exercise. It is a minimally invasive technique which is increasingly used around the world because it has almost no adverse effects compared to suburethral slings. The product is injected pre-urethrally and under local anesthesia. The results in terms of improvement are around 70% without knowing why certain patients are improved, slightly improved or not improved at all. One of the hypotheses is that a proportion of the product could be eliminated, and thus the mechanical effect would be reduced. Perineal ultrasound performed in routine practice allows the quantity of gel to be measured in 3 dimensions immediately post-operatively and at 3 months. The objective of this study is to compare the volume of gel between the immediate post-operative and 3 months and to correlate it with clinical results of improvement.
983 studies on the registry are indexed under Urinary Incontinence; 180 are open to participants now.
This study's enrollment of 40 is below the median of 120 across 215 observational studies indexed under Urinary Incontinence.
Browse Urinary Incontinence studies →Hospices Civils de Lyon is the lead sponsor of 1,866 studies on the registry; 448 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study covers all patients who received an injection of Bulkamid® peri-urethral filler for urinary incontinence between January 2024 and December 2025.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
women over 18
inability to understand the information given
patients who received an injection of Bulkamid® for urinary incontinence
volume of Bulkamid
Time frame: 3 months after injection
Ran from Jan 2026 to primary completion in Feb 2026, 1 month.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.